Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocodone SCHEMBL277572 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL1560734 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL10440385 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL6744988 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12513789 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL13091350 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL9890036 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12369421 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL21335350 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL101731 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527858-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2016-12-27 | — | — | US | disclosed |
| US-20140370006-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | SpecGx LLC | 2014-12-18 | — | — | US | disclosed |
| US-8829020-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2393783-B1 | PROCESS FOR PREPARING HYDROCODONE USING A SUPER ACID | MALLINCKRODT LLC (US) | 2014-04-30 | — | — | EP | disclosed |
| US-8563727-B2 | (+)-morphinanium N-oxides and processes for their production | MALLINCKRODT LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563727-B2 | (+)-morphinanium N-oxides and processes for their production | MALLINCKRODT LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-8367827-B2 | Process for preparing hydrocodone using a super acid | MALLINCKRODT LLC (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120129879-A1 | Compounds and Compositions for Use in Phototherapy and in Treatment of Ocular Neovascular Disease and Cancers | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2012-05-24 | — | — | US | disclosed |
| WO-2011009020-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | MALLINCKRODT INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015219-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | MALLINCKRODT INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100216997-A1 | (+)-Morphinanium N-Oxides and Processes for their Production | MALLINCKRODT INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216997-A1 | (+)-Morphinanium N-Oxides and Processes for their Production | MALLINCKRODT INC. (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010096790-A1 | (+)-MORPHINANANIUM N-OXIDES AND PROCESSES FOR THEIR PRODUCTION | MALLINCKRODT INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010065441-A1 | PROCESS FOR PREPARING HYDROCODONE USING A SUPER ACID | MALLINCKRODT INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100137598-A1 | Process for Preparing Hydrocodone Using a Super Acid | MALLINCKRODT INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137598-A1 | Process for Preparing Hydrocodone Using a Super Acid | MALLINCKRODT INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137598-A1 | Process for Preparing Hydrocodone Using a Super Acid | HAAO, CYP7A1, CYP3A5 | OPRD1 157/4885OPRM1 21/4885OPRK1 34/4885 |
| US-20140370006-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | VEGFA, OPRL1, OGFR | OPRD1 9/4885OPRM1 5/4885OPRK1 4/4885 |
| US-20100216997-A1 | (+)-Morphinanium N-Oxides and Processes for their Production | NPM1, NCL, NCLN | OPRD1 329/4885OPRM1 66/4885OPRK1 702/4885 |
| US-20120129879-A1 | Compounds and Compositions for Use in Phototherapy and in Treatment of Ocular Neovascular Disease and Cancers | VEGFA, OPRL1, OGFR | OPRD1 9/4885OPRM1 5/4885OPRK1 4/4885 |
| US-20110015219-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | TLR9, TLR3, TLR1 | OPRD1 51/4885OPRM1 17/4885OPRK1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.